CD39 and CD73 as promising therapeutic targets : what could be the limitations?

dc.contributor.author	Battastini, Ana Maria Oliveira	pt_BR
dc.contributor.author	Figueiró, Fabrício	pt_BR
dc.contributor.author	Leal, Daniela Bitencourt Rosa	pt_BR
dc.contributor.author	Doleski, Pedro Henrique	pt_BR
dc.contributor.author	Schetinger, Maria Rosa Chitolina	pt_BR
dc.date.accessioned	2021-06-02T04:33:14Z	pt_BR
dc.date.issued	2021	pt_BR
dc.identifier.issn	1663-9812	pt_BR
dc.identifier.uri	http://hdl.handle.net/10183/221805	pt_BR
dc.format.mimetype	application/pdf	pt_BR
dc.language.iso	eng	pt_BR
dc.relation.ispartof	Frontiers in pharmacology. Lausanne. Vol. 12 (Mar. 2021), 633603, 5 p.	pt_BR
dc.rights	Open Access	en
dc.subject	5'-nucleotidase	pt_BR
dc.subject	CD39	en
dc.subject	CD73	en
dc.subject	Nucleosideos	pt_BR
dc.subject	Inhibitors	en
dc.subject	Nucleotídeos	pt_BR
dc.subject	Purinergic system	en
dc.subject	Therapeutic approach	en
dc.subject	Limitations	en
dc.title	CD39 and CD73 as promising therapeutic targets : what could be the limitations?	pt_BR
dc.type	Artigo de periódico	pt_BR
dc.identifier.nrb	001125538	pt_BR
dc.type.origin	Estrangeiro	pt_BR

Este item está licenciado na Creative Commons License